CKChristian Kassasseya

Christian Kassasseya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Kassasseya has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vascular Geometry Drives Stroke Risk in Sickle Cell Disease

    by Weiqiang Liu, Christian Kassasseya, Lazaros Papamanolis, Kim‐Anh Nguyen‐Peyre, Morgane Garreau, Saskia Eckert, Gonzalo De Luna, Thomas D'HUmières, Vincent de Pierrefeu, Cecile Arnaud, et al.

    Sickle cell disease (SCD) is the leading cause of stroke in children and young adults, primarily due to cerebral vasculopathy (CV) occurring within the first decade of life. The main risk factor for CV is elevated blood velocity in intracranial arteries, contributing to stenosis formation in very young children. This study addresses three key questions: (i) the relationship between hemoglobin levels and intracranial blood velocities in SCD patients, (ii) additional factors contributing to elevated velocity beyond anemia, and (iii) the presence of flow anomalies. To investigate these aspects, biological and transcranial Doppler data from pediatric and adult SCD patients were analyzed. An image‐based in silico modeling approach was also developed to simulate blood flow in the internal carotid, anterior cerebral, and middle cerebral arteries of SCD patients, of different age classes, and prior to any possible stenosis. Analysis revealed that while anemia is a recognized CV risk factor, it does not fully explain elevated velocities, as no significant correlation was found in children under five. In in silico simulations, young patients reached pathological arterial intracranial velocities at physiological flow rates, whereas adults remained below risk thresholds even at high flow rates. Pathological velocities were primarily observed in distal internal carotid arteries, where stenoses often develop. High flow rates, small arterial diameters, and pronounced curvatures led to extreme velocities and complex flow, likely causing endothelial damage and promoting CV progression. These findings enhance understanding of hemodynamic mechanisms underlying SCD‐related stroke risk, paving the way for improved predictive models and early interventions. Trial Registration: ClinicalTrials.gov identifier: NCT05199766.


  • Misdiagnosis of thrombotic microangiopathy in the emergency department: a multicenter retrospective study

    by Isaure de Boisriou, Sami Ellouze, Christian Kassasseya, Anne-Laure Feral-Pierssens, Camille Gerlier, Anthony Chauvin, Sebastien Beaune, Evelyne Dubreucq, Laurent Pereira, Richard Chocron, et al.

    To estimate the rate of inappropriate diagnosis in patients who visited the ED with thrombotic microangiopathy (TMA) and to assess the factors and outcomes associated with emergency department (ED) misdiagnosis. Retrospective multicenter study of adult patients admitted to the intensive care unit (ICU) for TMA from 2012 to 2021 who had previously attended the ED for a reason related to TMA. Patient characteristics and outcomes were compared in a univariate analysis based on whether a TMA diagnosis was mentioned in the ED or not. Forty patients were included. The diagnosis of TMA was not mentioned in the ED in 16 patients (40%). Patients for whom the diagnosis was mentioned in the ED had more frequently a request for schistocytes research, and therefore had more often objectified schistocytes. They also had more frequently a troponin dosage in the ED (even if the difference was not significant), an ECG performed or interpreted, and were admitted more quickly in the ICU (0 [0–0] vs 2 [0–2] days; P = 0.002). Hemoglobin levels decreased significantly in both groups, and creatinine levels increased significantly in the misdiagnosis group between ED arrival and ICU admission. In patients with a final diagnosis of TTP, the time to platelets durable recovery was shorter for those in whom the diagnosis was mentioned in the ED without reaching statistical significance (7 [5–11] vs 14 [5–21] days; P = 0.3).


  • Prise en charge d’un patient drépanocytaire aux urgences

    by C. Kassasseya, S. Bressand, M. Khellaf

    La drépanocytose est aujourd’hui la première maladie génétique en France avec environ 30 000 patients adultes. Une mutation ponctuelle sur le chromosome 11 conduit à la production d’une hémoglobine pathologique qui polymérise sous l’effet de facteurs endo-ou exogènes induisant la falciformation des globules rouges à l’origine d’une vasoocclusion artérielle dont une des conséquences est l’oblitération des vaisseaux à destinée osseuse. Les infarctus osseux sont particulièrement douloureux, conduisant les patients aux urgences où l’enjeu est de soulager rapidement les douleurs par l’utilisation de morphine principalement par analgésie autocontrôlée après titration morphinique. Le risque majeur au cours de ces crises vaso-occlusives (CVO) est l’apparition d’un syndrome thoracique aigu (STA) pouvant mettre en jeu le pronostic vital du patient. La spirométrie incitative est un moyen préventif du STA important à instituer dès les urgences. Une antibiothérapie sera mise en place en cas de fièvre chez ces patients aspléniques à risque d’infections à germes encapsulés notamment par le pneumocoque. L’échange transfusionnel est une des pierres angulaires du traitement des CVO ou du STA mais le risque d’accident hémolytique aigu post transfusionnel doit en limiter l’usage à des situations mettant en jeu le pronostic vital ou fonctionnel d’organe. Plusieurs scores clinicobiologiques permettent de décider de l’utilité d’un angioscanner thoracique au cours du STA à la recherche d’une embolie pulmonaire ou pour décider de la pertinence d’une sortie vers une hospitalisation à domicile (Programme DREPADOM). L’utilisation de la morphine en dehors de l’hôpital de façon prolongée doit être prudente en raison du risque d’addiction.

  • Top Cited Papers
    Open Access

    Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments

    by Donia Bouzid, Benoit Visseaux, Christian Kassasseya, Asma Daoud, Florent Fémy, Christelle Hermand, Jennifer Truchot, Sebastien Beaune, Nicolas Javaud, Olivier Peyrony, et al.

    At the end of 2021, infections with the B.1.1.529 SARS-CoV-2 variant (Omicron) superseded those with the B.1.617.2 variant (Delta). This study compares baseline characteristics and in-hospital outc... Visual Patients With Delta Versus Omicron Variants in the Emergency Department. At the end of 2021, infections with the B.1.1.529 SARS-CoV-2 variant (Omicron) superseded those with the B.1... Background: At the end of 2021, the B.1.1.529 SARS-CoV-2 variant (Omicron) wave superseded the B.1.617.2 variant (Delta) wave. Objective: To compare baseline characteristics and in-hospital outcome...


  • Open Access

    Association between benzodiazepine outpatient treatment and risk of early seizure recurrence in emergency patients with seizure: A multicenter retrospective study

    by Melanie Roussel, Anthony Chauvin, Pierrick Le Borgne, Marie Drogrey, Xavier Eyer, Ulysse Hatabian, Christophe Choquet, Olivier Peyrony, Laura Luhmann, Christian Kassasseya, et al.

    Introduction Seizures are one of the most common neurological reasons for emergency department (ED) visits. The benefit of ED‐initiated, short‐course outpatient benzodiazepine (BZD) treatment to prevent early recurrent seizure is unknown. This study assesses the risk of early seizure recurrence in patients who were or were not started with outpatient BZD in the ED. Methods This was a multicenter retrospective study conducted in eight French EDs between January 1 and December 31, 2019. All patients admitted for seizure were retrospectively screened and those discharged home from the ED were included. Patients with a history of chronic alcohol intoxication or chronic BZD therapy were excluded. Baseline characteristics, type of seizure, and 30‐day outcome were retrospectively collected from the electronic health records. The primary endpoint was a return visit for seizure recurrence within 30 days. Independent factors associated with a seizure recurrence were identified using a multivariable binary logistic regression. Results A total of 2,218 patients were included and 1,820 were analyzed. The median age was 39 years and 60% were men. Among them 82% of patients had a generalized tonic–clonic seizure and 47% of seizures were idiopathic. BZD treatment was started in 773 (42%) patients. A total of 154 (8%) patients had an early recurrence at 30 days: 68 (9%) in patients who were treated with BZD versus 86 (8%) in patients who were not (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 0.71 to 1.43). In multivariable analysis, two factors were independently associated with the primary endpoint: chronic epileptic treatment (adjusted OR = 2.58, 95% CI = 1.55 to 4.37) and having had a focal seizure (adjusted OR = 2.16, 95% CI = 1.56 to 4.37). Conclusion BZD therapy was started in 42% of patients who were discharged home after ED visit for a seizure. This treatment was not an independent factor associated with the risk of return visit for seizure recurrence at 30 days.